Invest in Meenorio
For institutional and angel investors interested in Pakistan-headquartered evidence-based herbal medicine.
The Opportunity
Pakistan has 33 million adults living with diabetes (IDF 2023) and another ~11 million in pre-diabetic territory. The country sits at one of the highest diabetes-prevalence rates in the world. The market for diabetes-related products is massive but fragmented — international pharma sells branded medications, local pharmacies sell generic equivalents and unregulated herbal products. There is no PK-headquartered, evidence-based, regulatorily-compliant herbal supplement brand operating at scale.
Meenorio is building that company.
Strategic Positioning
Mission anchor: standardize herbal medicine to be evidence-equivalent to allopathic medicine. Multi-decade project. Anchors every product decision: HbA1c-anchored efficacy, transparent formulation, regulatory compliance, claim-conservative marketing.
Product strategy: Metabo-101 (our first product) demonstrates the model works. The catalogue is the moat: a multi-product DRAP-licensed evidence-based herbal portfolio takes years to reproduce.
Independent research as a long-term moat: we fund USD 1,000-per-project research grants for student and faculty research globally. Researchers retain publication rights regardless of outcome. Over 5–10 years, the result is an independent body of literature that compounds into academic credibility — a moat no traditional supplement company is building.
Capital Strategy
Meenorio runs two parallel capital streams: investor capital funds growth (sales, marketing, catalogue expansion); donor capital funds mission programmes (translations, awareness camps, free product for low-income patients, research grants). The two streams are accounted for separately. Investor capital is never used for mission programmes; donor capital is never used for product development or marketing.
This separation is the structural insight: it lets investors and donors each contribute to the parts they care about without subsidising each other.
Investment Opportunities Available
We work with a range of investor profiles. Two structures are currently open:
- Short-term (6 months to 3 years). Fixed-tenor, return-bearing instruments suited to investors looking for medium-horizon deployment with structured exit.
- Long-term (equity-based). Equity participation for investors aligned with the multi-decade mission and comfortable with the typical liquidity timeline of an early-stage growth company.
Minimum bite size: PKR 500,000. Both structures available at this entry point and above.
We deliberately keep specific terms, valuations, traction numbers, and the deck off the public web. They're shared with serious investors after a brief introductory exchange — alignment with the mission matters as much as capital.
The Team
Meenorio is a Pakistani team of formulators, scientists, growth operators, and operations leads. We deliberately don't lead the brand with a founder face — the brand stands on certifications, scientific process, and independent voices, not on personal narrative. This is a strategic choice, not a default.
For investor due diligence, our team's individual backgrounds are documented in the investor materials shared after initial inquiry. NDA is mutual.
Get In Touch
Email invest@meenorio.com with:
- Your fund / firm name (or angel investor self-introduction)
- Which structure interests you — short-term, long-term equity, or both
- Approximate cheque-size you're considering (any amount at or above PKR 500,000)
- Sector focus and stage focus, if institutional
- Any specific questions you'd want addressed before we share materials
We respond to qualified inquiries within 3 business days. Initial conversation is informal — we want to understand your alignment with the mission before sharing operational specifics.
Frequently Asked Questions
Why don't you publish the deck or specific traction numbers?
Two reasons. First, our positioning is institutional and conservative; loud public valuation talk is incongruent with the brand voice. Second, traction numbers move month to month; investors who see a snapshot online and use it to anchor their valuation expectations are usually 90 days behind reality. We share current state in conversation.
Is Meenorio fundraising right now?
Meenorio is in continuous conversation with potential investors across both structures. Whether we're actively closing a round at any moment depends on capital needs vs. current runway. Email us regardless — even if we're not closing immediately, building the relationship matters.
What stage is the company at?
Revenue-generating, post-product-market-fit on the first SKU. Specific financials in the materials shared after initial inquiry.
What's the use of investor capital?
Three primary buckets: (1) Meta + Google paid acquisition with a clear CAC-reduction roadmap; (2) catalogue expansion — second SKU launch within 12 months of close; (3) team — bringing in clinical, ops, and tech talent to scale operations. Specifics shared in materials.
What's the exit story?
Multiple plausible paths depending on which structure you're in: short-term instruments have a defined return + tenor; equity has the typical paths (PE / strategic acquirer in supplement or pharma; IPO if catalogue scale supports it; founder-led long-term hold with quarterly distributions). We optimise for building a durable, mission-aligned company first; exit is a function of that durability, not the goal.
Who are the existing investors?
Detailed in the materials shared after introduction. We're selective about additional investors — alignment with the mission matters as much as capital.